Our website has detected that you are using an outdated browser that will prevent you from accessing certain features.
Please use one of the below recommended browsers to improve your browsing experience
Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for non-Hodgkin's lymphoma in The Netherlands
Franken M, Kanters T, Uyl- de Groot C. Institute for Medical Technology Assessment
Our website has detected that you are using an outdated browser that will prevent you from accessing certain features. Please use one of the below recommended browsers to improve your browsing experience
English
Chinese
